News
ABUS
2.900
-1.69%
-0.050
BEAM, ABUS and EGHT are among after hour movers
Seeking Alpha · 1d ago
Chardan Capital Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
TipRanks · 4d ago
Arbutus Biopharma (ABUS) Receives a Buy from JMP Securities
TipRanks · 01/05 18:15
BRIEF-Arbutus Announces 2023 Corporate Objectives And Provides Financial Update
Reuters · 01/05 12:31
BRIEF-Arbutus Completes Enrollment In Its Phase 2A Clinical Trial For AB-729 Combination Therapy In Patients With Chronic Hepatitis B Infection
Reuters · 12/13/2022 12:49
Arbutus Completes Enrollment In Its Phase 2a Clinical Trial Combining AB-729 With NA Therapy And Peginterferon alfa-2a in Patients With Chronic Hepatitis B Virus Infection
Benzinga · 12/13/2022 12:36
Arbutus Biopharma Says Data Reinforces Antigen-Reducing Capacity of Chronic Hepatitis B Virus Treatment
Arbutus Biopharma Says Data Reinforces Antigen-Reducing Capacity of Chronic Hepatitis B Virus Treatment
MT Newswires · 12/13/2022 10:58
Arbutus Biopharma's Return On Capital Employed Insights
Benzinga · 12/12/2022 14:46
Companies Like Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 12/08/2022 11:34
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Benzinga · 12/06/2022 12:36
Arbutus Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma ( NASDAQ:ABUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.95m (up 78% from 3Q...
Simply Wall St. · 11/11/2022 10:20
HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Lowers Price Target to $6
Benzinga · 11/10/2022 11:27
--HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating
MT Newswires · 11/10/2022 09:55
Arbutus trades higher as Q3 net loss narrows, revenue grows on license deal
Seekingalpha · 11/09/2022 17:26
BRIEF-Arbutus Reports Q3 Financial Results, Provides Corporate Update
Reuters · 11/09/2022 14:55
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09/2022 13:45
Arbutus Biopharma GAAP EPS of -$0.12 beats by $0.01, revenue of $5.95M misses by $3.23M
Seekingalpha · 11/09/2022 12:40
Arbutus Biopharma Q3 EPS $(0.12) Beats $(0.13) Estimate, Sales $5.95M Miss $9.37M Estimate
Benzinga · 11/09/2022 12:31
-- Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $6M, vs. Street Est of $9.2M
-- Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $6M, vs. Street Est of $9.2M
MT Newswires · 11/09/2022 07:43
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).